Recent advances of drug delivery nanocarriers in osteosarcoma treatment

Osteosarcoma is the most common primary malignant bone tumor mainly occurred in children and adolescence, and chemotherapy is limited for the side effects and development of drug resistance. Advances in nanotechnology and knowledge of cancer biology have led to significant improvements in developing...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Cancer 2020, Vol.11 (1), p.69-82
Main Authors: Wang, Shang-Yu, Hu, Hong-Zhi, Qing, Xiang-Cheng, Zhang, Zhi-Cai, Shao, Zeng-Wu
Format: Article
Language:English
Subjects:
Acids
Biocompatibility
Bone cancer
Cancer therapies
Chemotherapy
Clinical trials
Drug delivery systems
Drug dosages
FDA approval
Keratin
Lipids
Nanomaterials
Nanoparticles
Polyethylene glycol
Polymers
Review
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Osteosarcoma is the most common primary malignant bone tumor mainly occurred in children and adolescence, and chemotherapy is limited for the side effects and development of drug resistance. Advances in nanotechnology and knowledge of cancer biology have led to significant improvements in developing tumor-targeted drug delivery nanocarriers, and some have even entered clinically application. Delivery of chemotherapeutic agents by functionalized smart nanocarriers could protect the drugs from rapid clearance, prolong the circulating time, and increase the drug concentration at tumor sites, thus enhancing the therapeutic efficacy and reducing side effects. Various drug delivery nanocarriers have been designed and tested for osteosarcoma treatment, but most of them are still at experimental stage, and more further studies are needed before clinical application. In this present review, we briefly describe the types of commonly used nanocarriers in osteosarcoma treatment, and discuss the strategies for osteosarcoma-targeted delivery and controlled release of drugs. The application of nanoparticles in the management of metastatic osteosarcoma is also briefly discussed. The purpose of this article is to present an overview of recent progress of nanoscale drug delivery platforms in osteosarcoma, and inspire new ideas to develop more effective therapeutic options.
ISSN:1837-9664
1837-9664
DOI:10.7150/jca.36588